Compare PIII & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PIII | BTMD |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 39.0M |
| IPO Year | 2021 | 2021 |
| Metric | PIII | BTMD |
|---|---|---|
| Price | $3.99 | $1.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $18.00 | $2.61 |
| AVG Volume (30 Days) | 13.7K | ★ 104.7K |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 722.22 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,459,080,000.00 | $192,219,000.00 |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | $9.37 | $5.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.52 | $1.00 |
| 52 Week High | $16.89 | $2.98 |
| Indicator | PIII | BTMD |
|---|---|---|
| Relative Strength Index (RSI) | 32.26 | 44.37 |
| Support Level | $3.81 | $1.01 |
| Resistance Level | $4.14 | $1.68 |
| Average True Range (ATR) | 0.48 | 0.11 |
| MACD | 0.13 | 0.02 |
| Stochastic Oscillator | 22.33 | 49.08 |
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all. It includes utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.